JNCCN 360 - Ovarian - Ongoing CE Activities

Editor:

Theresa L. Werner, MD

Advertisement

Advertisement

Ongoing CE Activities

Advances in™ PARP Inhibitors: Expanding the Application of Novel Agents in Ovarian Cancer

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care-Ovarian Cancer

Cancer Summaries and Commentaries™: Recent Advances in the Treatment of Gynecological Cancers: What we Learned in Barcelona

Current and Future Directions in PARP Inhibition

Exploring the Evolving Role of PARP Inhibition and Immunotherapy in Gynecological Cancers

Genetic Familial High-Risk Assessment Breast Ovarian And Pancreatic Version 1.2020

Community Practice Connections™: Managing Postoperative Pain: The Clinical Impact of Opioid-Sparing Strategies on Patients With Breast Cancer

Modest Responses With Immunotherapy Combo for Advanced Ovarian Cancer

NCCN Guidelines® Insights - Ovarian Cancer, Version 1.2019

Ovarian Cancer: Therapeutic Updates, Best Practices, and Emerging Treatments

Ovarian Cancer Tumor Board: Leveraging Evolving Data Sets on PARP Inhibitors in Ovarian Cancer to Inform Treatment Decision-Making

Risk Stratification for Breast and Ovarian Cancer

Second Surgery in Recurrent Ovarian Cancer Did Not Lead to Survival Benefit

Selection of Optimal First-Line and Maintenance therapy in Advanced Ovarian Cancer

Sections

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.